Definitive single fraction stereotactic ablative radiotherapy for inoperable early-stage breast cancer: A case report

Veluvolu, Manasa; Patel, Mausam; Narayanasamy, G.; Kim, Thomas

doi:10.1016/j.rpor.2020.06.011

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Veluvolu et al [37] present the case of a patient with a cT2, N0 BC, who resulted to be inoperable due to comorbidities. The total dose administered was 25 Gy in single fraction.…”

Section: Resultsmentioning

confidence: 99%

Stereotactic Radiotherapy in Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review

Piras¹,

Sanfratello²,

Boldrini

et al. 2022

Oncol Res Treat

View full text Add to dashboard Cite

Introduction Breast cancer (BC) is one of the most common tumours, better screening policies and multidisciplinary approach allow personalised treatment. Radiotherapy (RT) plays a central role in the multimodal approach in BC, and recent evidence have shown the non-inferiority of hypofractionated treatments. The aim of this study is to describe the feasibility and validity of stereotactic RT (SBRT) in BC in neoadjuvant and exclusive setting. Methods A Pubmed/MEDLINE and Embase systematic review was conducted to assess the role of radiomics in BC. The search strategy was “breast [All Fields] AND "stereotactic" [All Fields] AND "radiotherapy" [All Fields])” and only original articles referred to BC in humans in the English language were considered. Results A total of 2149 studies were obtained using the mentioned search strategy on Pubmed and Embase. After the complete selection process, a total of 12 papers were considered eligible for the analysis of the results. SBRT in BC was described in 8 studies regarding neoadjuvant approach and 4 papers regarding exclusive approach. Conclusions Relative low toxicity rates; the reduced treatment volumes in the neoadjuvant setting and the possibility to replace surgery when not feasible in exclusive setting, resulted to be main advantages for SBRT in BC. Current evidence showed as both the neoadjuvant and the definitive settings seem to be promising clinical scenarios for SBRT especially for EBC.

show abstract

“…Veluvolu et al [37] present the case of a patient with a cT2, N0 BC, who resulted to be inoperable due to comorbidities. The total dose administered was 25 Gy in single fraction.…”

Section: Resultsmentioning

confidence: 99%